KDM1A and acute myeloid leukemia: To improve the potency and selectivity of TCP toward LSD1, derivatives active in the nanomolar range have been developed (Guibourt et al., 2010, Johnson and Kasparec, 2012, Maiques-Diaz and Somervaille, 2016), and these have shown significant promise as differentiation-inducing agents in pre-clinical studies in acute myeloid leukemia (AML) (Harris et al., 2012, Schenk et al., 2012).